Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson’s disease

References

• Afshin-Majd S, Bashiri K, Kiasalari Z, et al. (2017). Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat. Biomed Pharmacother 89:1–9.
   PubMed Web of Science ®Google Scholar
• Avachat AM, Kapure SS. (2014). Asenapine maleate in situ forming biodegradable implant: an approach to enhance bioavailability. Int J Pharm 477:64–72.
   PubMed Web of Science ®Google Scholar
• Bege N, Renette T, Endres T, et al. (2013). In situ forming nimodipine depot system based on microparticles for the treatment of posthemorrhagic cerebral vasospasm. Eur J Pharm Biopharm 84:99–105.
   PubMed Web of Science ®Google Scholar
• Bisht R, Jaiswal JK, Rupenthal ID. (2017). Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye. Med Hypotheses 103:5–9.
   PubMed Web of Science ®Google Scholar
• Cavazzuti M. 2013. Design of experiments. 13–42.
   Google Scholar
• Collaborators IP. (2016a). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of disease study 2015. Lancet 388:1545–602.
   PubMed Web of Science ®Google Scholar
• Collaborators MCOD. (2016b). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of disease study 2015. Lancet 388:1459–544.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670
   PubMed Web of Science ®Google Scholar
• Dashtipour K. (2007). Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Therapeut 29:1825.
   PubMed Web of Science ®Google Scholar
• David B, Fong JW, Thomas K, et al. 1997. Sustained release formulations of water soluble peptides.
   Google Scholar
• Ellis JM, Fell MJ. (2017). Current approaches to the treatment of Parkinson’s disease. Bioorg Med Chem Lett 27:4247–55.
   PubMed Web of Science ®Google Scholar
• Fernandez M, Barcia E, Fernandez-Carballido A, et al. (2012). Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease. Int J Pharm 438:266–78.
   PubMed Web of Science ®Google Scholar
• Fernandez M, Barcia E, Negro S. (2009). Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres. J Pharm Biomed Anal 49:1185–91.
   PubMed Web of Science ®Google Scholar
• Fernandez M, Negro S, Slowing K, et al. (2011). An effective novel delivery strategy of rasagiline for Parkinson's disease. Int J Pharm 419:271–80.
   PubMed Web of Science ®Google Scholar
• Garbayo E, Ansorena E, Blanco-Prieto MJ. (2013). Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems. Maturitas 76:272.
   PubMed Web of Science ®Google Scholar
• Juvekar S, Kathpalia H. (2017). Solvent removal precipitation based in situ forming implant for controlled drug delivery in periodontitis. J Control Release 251:75–81.
   PubMed Web of Science ®Google Scholar
• Karfeld-Sulzer LS, Ghayor C, Siegenthaler B, et al. (2015). N-methyl pyrrolidone/bone morphogenetic protein-2 double delivery with in situ forming implants. J Control Release 203:181–8.
   PubMed Web of Science ®Google Scholar
• Lin X, Xu Y, Tang X, et al. (2015). A uniform ultra-small microsphere/SAIB hybrid depot with low burst release for long-term continuous drug release. Pharm Res 32:3708–21.
   PubMed Web of Science ®Google Scholar
• Ma J, Chen X, Duan X, et al. (2008). Validated LC–MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. J Chromatogr B 873:203–8.
   PubMed Web of Science ®Google Scholar
• Marsili L, Marconi R, Colosimo C. (2017). Treatment strategies in early Parkinson's disease. Int Rev Neurobiol 132:345–60.
   PubMed Web of Science ®Google Scholar
• Ng SM, Choi JY, Han HS, et al. (2010). Novel microencapsulation of potential drugs with low molecular weight and high hydrophilicity: hydrogen peroxide as a candidate compound. Int J Pharm 384:120–7.
   PubMed Web of Science ®Google Scholar
• Paillard-Giteau A, Tran VT, Thomas O, et al. (2010). Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s/o/w emulsion technique. Eur J Pharm Biopharm 75:128–36.
   PubMed Web of Science ®Google Scholar
• Ravi PR, Aditya N, Patil S, Cherian L. (2015). Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv 22:903–10.
   PubMed Web of Science ®Google Scholar
• Thakur RRS, Mcmillan HL, Jones DS. (2014). Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. J Control Release 176:8–23.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang A, Zhao X, et al. (2012). Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism. Int J Pharm 427:284–92.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhuo X, Chu W, Tang X. (2017). Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity. Int J Pharm 528:62–75.
   PubMed Web of Science ®Google Scholar
• Wang T, Yang L, Hua J, et al. (2016). Simultaneous bioanalysis of rasagiline and its major metabolites in human plasma by LC–MS/MS: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 125:280–5.
   PubMed Web of Science ®Google Scholar
• Weinreb O, Badinter F, Amit T, et al. (2015). Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice. Neurobiol Aging 36:2628–36.
   PubMed Web of Science ®Google Scholar
• Yoram S, Nurit L, Itschak L, Tomer M. 2012. Extended release formulations of rasagiline and uses thereof US.
   Google Scholar